HealthCare Global Enterprises Ltd. (IN:HCG)
:HCG
Want to see IN:HCG full AI Analyst Report?
Top Page
HealthCare Global Enterprises Ltd.
(HCG)
Select Model
Select Model
Rating:62Neutral
Price Target:
₹691.00
▲(5.42% Upside)
Action:Reiterated
Date:05/21/26
The score is driven primarily by fair financial performance—strong cash generation and scaled revenue, but pressured by thin profitability and high leverage. Technicals are supportive with strong trend/momentum, while valuation is a notable drag due to a negative P/E and no dividend yield data.
Positive Factors
Oncology-focused hospital network
A dedicated oncology hospital network creates durable specialization benefits: concentrated clinical expertise, referral economies, and integrated diagnostic/treatment services. This structural positioning supports stable demand, deeper patient relationships and higher barriers to entry versus generalist providers.
Negative Factors
High leverage
Elevated and rising debt leaves earnings exposed to interest cost swings and limits strategic flexibility. For hospitals with steady capex needs, high leverage raises refinancing and covenant risks and makes profitability highly sensitive to operating volatility and reimbursement changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Oncology-focused hospital network
A dedicated oncology hospital network creates durable specialization benefits: concentrated clinical expertise, referral economies, and integrated diagnostic/treatment services. This structural positioning supports stable demand, deeper patient relationships and higher barriers to entry versus generalist providers.
Read all positive factors
HealthCare Global Enterprises Ltd. (HCG) vs. iShares MSCI India ETF (INDA)
Market Cap
₹93.61B
Dividend YieldN/A
Average Volume (3M)18.12K
Price to Earnings (P/E)541.4
Beta (1Y)0.49
Revenue Growth16.15%
EPS Growth-67.50%
CountryIN
Employees6,150
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)2.53
Shares Outstanding149,302,200
10 Day Avg. Volume16,611
30 Day Avg. Volume18,118
Financial Highlights & Ratios
PEG Ratio-7.78
Price to Book (P/B)5.59
Price to Sales (P/S)2.93
P/FCF Ratio135.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹710.00Price Target Upside8.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)9.55
Revenue Forecast (FY)₹29.13B
HealthCare Global Enterprises Ltd. Business Overview & Revenue Model
Company Description
HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertil...
How the Company Makes Money
HCG makes money primarily by delivering oncology-focused healthcare services to patients through its hospital network. Revenue is generated from fees charged for clinical services such as consultations, diagnostics (including imaging and laborator...
HealthCare Global Enterprises Ltd. Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
54
Neutral
Cash Flow
71
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.02B | 25.38B | 22.23B | 19.12B | 16.94B | 13.98B |
| Gross Profit | 11.85B | 12.97B | 11.91B | 10.48B | 9.20B | 7.52B |
| EBITDA | 3.72B | 4.48B | 3.13B | 2.67B | 2.37B | 1.78B |
| Net Income | 353.60M | 137.60M | 444.10M | 481.55M | 293.49M | 537.33M |
Balance Sheet | ||||||
| Total Assets | 35.86B | 39.23B | 35.43B | 27.07B | 23.16B | 22.20B |
| Cash, Cash Equivalents and Short-Term Investments | 2.02B | 5.52B | 3.53B | 3.03B | 1.97B | 2.04B |
| Total Debt | 17.68B | 17.35B | 18.37B | 12.74B | 9.01B | 9.15B |
| Total Liabilities | 25.92B | 25.12B | 25.53B | 18.42B | 14.47B | 13.36B |
| Stockholders Equity | 9.21B | 13.32B | 9.22B | 8.26B | 8.61B | 8.70B |
Cash Flow | ||||||
| Free Cash Flow | 339.30M | 550.00M | 1.08B | 988.99M | 1.18B | 1.49B |
| Operating Cash Flow | 1.92B | 3.47B | 3.17B | 2.85B | 2.52B | 2.20B |
| Investing Cash Flow | -580.00M | -1.77B | -4.88B | -2.26B | -1.33B | 1.25B |
| Financing Cash Flow | -806.50M | 2.41B | -424.40M | -640.16M | -1.40B | -1.55B |
HealthCare Global Enterprises Ltd. Technical Analysis
Positive
655.45
Price Trends
575.67
Positive
592.97
Positive
640.95
Positive
Market Momentum
20.00
Negative
65.26
Neutral
71.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HCG, the sentiment is Positive. The current price of 655.45 is above the 20-day moving average (MA) of 611.73, above the 50-day MA of 575.67, and above the 200-day MA of 640.95, indicating a bullish trend. The MACD of 20.00 indicates Negative momentum. The RSI at 65.26 is Neutral, neither overbought nor oversold. The STOCH value of 71.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HCG.
HealthCare Global Enterprises Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹394.15B | 75.82 | ― | 0.24% | 25.81% | -0.76% | |
66 Neutral | ₹333.32B | 46.41 | ― | 0.04% | 19.44% | 15.55% | |
63 Neutral | ₹392.92B | 61.58 | ― | 0.84% | 12.20% | -93.03% | |
62 Neutral | ₹93.61B | 541.44 | ― | ― | 16.15% | -67.50% | |
61 Neutral | ₹730.08B | 86.12 | ― | 0.11% | 15.99% | 24.81% | |
61 Neutral | ₹1.06T | ― | ― | 0.14% | 19.14% | 34.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:HCG
HealthCare Global Enterprises Ltd.
653.75
96.99
17.42%
IN:ASTERDM
Aster DM Healthcare Ltd.
756.30
210.86
38.66%
IN:FORTIS
Fortis Healthcare Ltd.
960.45
253.14
35.79%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,023.25
-149.15
-12.72%
IN:MEDANTA
Global Health Limited
1,238.50
33.43
2.77%
IN:NH
Narayana Hrudayalaya Ltd.
1,854.35
80.58
4.54%
HealthCare Global Enterprises Ltd. Corporate Events
HCG Extends Timeline for Additional 34% Stake Purchase in Vizag Cancer Hospital
Mar 29, 2026
HealthCare Global Enterprises Ltd. has signed second amendment agreements to its Share Purchase Agreement and Shareholders’ Agreement related to the acquisition of Vizag Hospital and Cancer Research Centre Private Limited. The amendments pri...
HealthCare Global Expands Equity Base with ₹512-Per-Share Rights Allotment
Mar 27, 2026
HealthCare Global Enterprises Ltd., a Bengaluru-based oncology-focused hospital chain with operations across India and in Kenya, has expanded its equity base through a recently completed rights issue to existing shareholders. The company provides ...
HealthCare Global Clears Rights Issue Offer to Raise Up to ₹424.7 Crore
Feb 24, 2026
HealthCare Global Enterprises Ltd. has finalized and filed its Letter of Offer for a rights issue of up to 8,294,566 fully paid equity shares, each with a face value of ₹10 priced at ₹512 including premium, to raise up to ₹42,468...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.